Table 2.

Primary and Secondary Outcomes in the VERROU-REA Study (N = 396)

Outcome	Citrate (N = 199)	Heparin (N = 197)	p value
Overall duration of the first catheter (days), median (Q1, Q3)a	7 (3, 10)	5 (3, 11)	0.51
First hemodialysis non-tunneled catheter-days, n	1461	1590
Fibrinolysis for the first non-tunneled hemodialysis catheter, n (%)	2 (1%)	0	1
Incidence rate per 1000 catheter-days	1.37	0
Bleeding at the insertion site of the catheter, n (%)	1 (1%)	5 (3%)	0.12
Incidence rate per 1000 catheter-days	0.68	3.14
Hematoma at the insertion site of the first catheter, n (%)	3 (2%)	1 (1%)	0.62
Incidence rate per 1000 catheter-days	2.05	0.63
Thrombosis of the first non-tunneled hemodialysis catheter, n (%)	9 (5%)	3 (2%)	0.14
Incidence rate per 1000 catheter-days	6.16	1.89
Local first catheter-related infection, n (%)	7 (14%)	8 (19%)	0.55
Incidence rate per 1000 catheter-days	4.79	5.03
General first catheter-related infection, n (%)	4 (8%)	1 (2%)	0.37
Incidence rate per 1000 catheter-days	2.74	0.63
First catheter-related bloodstream infection, n (%)	1 (2%)	0	1
Incidence rate per 1000 catheter-days	0.68	0
Heparin-induced thrombocytopenia	4 (2%)	2 (1%)	1
Bleeding events during follow-up	41 (21%)	37 (19%)	0.65
Requiring transfusion packs red blood cells	22 (11%)	27 (14%)	0.42
Requiring transfusion of ≥ 2 packs red blood cells	20 (10%)	26 (13%)	0.33
Death at 28 days, n (%)	88 (44%)	94 (48%)	0.49
Death in ICU, n (%)	84 (42%)	92 (47%)	0.37
Length of ICU stay (from randomization) (days), median (Q1, Q3)	6 (3, 14)	6 (3, 12)	0.70
In-hospital death, n (%)	102 (51%)	108 (55%)	0.48
Length of hospital stay (from randomization) (days), median (Q1, Q3)	15 (6, 31)	12 (4, 27)	0.18

^aKaplan–Meier estimation and log-rank test with one missing data in the Heparin arm